Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas
暂无分享,去创建一个
R. Advani | S. Horwitz | T. Illidge | N. Bartlett | A. Forero-Torres | M. Fanale | B. Pro | D. Huebner | A. Shustov | D. Kennedy | A. Davies | Robert Chen